Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 4.39
HSKA's Cash to Debt is ranked higher than
57% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. HSKA: 4.39 )
Ranked among companies with meaningful Cash to Debt only.
HSKA' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 0.77 Max: No Debt
Current: 4.39
Equity to Asset 0.64
HSKA's Equity to Asset is ranked higher than
59% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. HSKA: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
HSKA' s Equity to Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.58 Max: 0.78
Current: 0.64
0.02
0.78
Interest Coverage 76.74
HSKA's Interest Coverage is ranked higher than
50% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. HSKA: 76.74 )
Ranked among companies with meaningful Interest Coverage only.
HSKA' s Interest Coverage Range Over the Past 10 Years
Min: 1.89  Med: 12.04 Max: 42.79
Current: 76.74
1.89
42.79
F-Score: 5
Z-Score: 5.93
M-Score: -2.06
WACC vs ROIC
5.62%
12.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 11.29
HSKA's Operating margin (%) is ranked higher than
74% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.14 vs. HSKA: 11.29 )
Ranked among companies with meaningful Operating margin (%) only.
HSKA' s Operating margin (%) Range Over the Past 10 Years
Min: -1.83  Med: 3.67 Max: 8.18
Current: 11.29
-1.83
8.18
Net-margin (%) 7.55
HSKA's Net-margin (%) is ranked higher than
75% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. HSKA: 7.55 )
Ranked among companies with meaningful Net-margin (%) only.
HSKA' s Net-margin (%) Range Over the Past 10 Years
Min: -1.53  Med: 2.67 Max: 42.28
Current: 7.55
-1.53
42.28
ROE (%) 13.22
HSKA's ROE (%) is ranked higher than
79% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.49 vs. HSKA: 13.22 )
Ranked among companies with meaningful ROE (%) only.
HSKA' s ROE (%) Range Over the Past 10 Years
Min: -2.49  Med: 4.84 Max: 140.27
Current: 13.22
-2.49
140.27
ROA (%) 7.97
HSKA's ROA (%) is ranked higher than
80% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.98 vs. HSKA: 7.97 )
Ranked among companies with meaningful ROA (%) only.
HSKA' s ROA (%) Range Over the Past 10 Years
Min: -1.49  Med: 3.03 Max: 61.02
Current: 7.97
-1.49
61.02
ROC (Joel Greenblatt) (%) 38.24
HSKA's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.85 vs. HSKA: 38.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HSKA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5.69  Med: 14.71 Max: 29.5
Current: 38.24
-5.69
29.5
Revenue Growth (3Y)(%) 3.70
HSKA's Revenue Growth (3Y)(%) is ranked higher than
51% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. HSKA: 3.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HSKA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.9  Med: 1.5 Max: 10.4
Current: 3.7
-16.9
10.4
EBITDA Growth (3Y)(%) 37.30
HSKA's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. HSKA: 37.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HSKA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.9  Med: -21.7 Max: 37.3
Current: 37.3
-63.9
37.3
EPS Growth (3Y)(%) 49.80
HSKA's EPS Growth (3Y)(%) is ranked higher than
94% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. HSKA: 49.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HSKA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -35.55 Max: 49.8
Current: 49.8
0
49.8
» HSKA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

HSKA Guru Trades in Q4 2015

Jim Simons 231,580 sh (+7.50%)
Mario Gabelli 50,200 sh (-0.40%)
» More
Q1 2016

HSKA Guru Trades in Q1 2016

Mario Gabelli 50,200 sh (unchged)
Jim Simons 180,781 sh (-21.94%)
» More
Q2 2016

HSKA Guru Trades in Q2 2016

Mario Gabelli 50,200 sh (unchged)
Jim Simons 121,680 sh (-32.69%)
» More
Q3 2016

HSKA Guru Trades in Q3 2016

Chuck Royce 37,000 sh (New)
Mario Gabelli 48,200 sh (-3.98%)
Jim Simons 38,180 sh (-68.62%)
» More
» Details

Insider Trades

Latest Guru Trades with HSKA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:NVDQ, NAS:NRCIA, NAS:BEAT, NAS:LNTH, NAS:ONVO, NAS:SRDX, NAS:OXFD, NYSE:ENZ, NAS:RDNT, NAS:TRIB, NAS:NTRA, AMEX:SENS, NYSE:NVTA, NYSE:ARA, NAS:TTOO, NAS:VIVO, NAS:NEO, NAS:QDEL, NAS:CTSO, NAS:PMD » details
Traded in other countries:HSKN.Germany,
Heska Corp is engaged in developing, manufacturing, marketing, selling and supporting veterinary products. The Company's core focus is on the canine and feline companion animal health markets.

Heska Corp was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. The Company develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it provides high value products. The Company's business is comprised of two reportable segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment includes mainly for canine and feline use, blood testing instruments and supplies as well as single use products and services such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. These products are sold directly to veterinarians by the Company as well as through distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals. All OVP products are sold by third parties under third party labels. It provides line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases and Electrolytes; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is a blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The Element POC Blood Gas & Electrolyte Analyzer is a handheld, wireless analyzer which delivers rapid blood gas, electrolyte, metabolite, and basic blood chemistry testing. EPOC features test cards with room temperature storage which can provide results with less than 100 uL of sample as well as WiFi and Bluetooth connectivity. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories in Loveland, Colorado and Fribourg, Switzerland which both provide blood testing using its ALLERCEPT Definitive Allergen Panels. Its competitors include: IDEXX Laboratories, Inc., Abaxis, Inc. and Synbiotics Corporation. The Company may be or subject to extensive regulation by governmental authorities in the United States, including the USDA and the FDA, and by similar agencies in other countries.

Ratios

vs
industry
vs
history
P/E(ttm) 52.21
HSKA's P/E(ttm) is ranked lower than
80% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.96 vs. HSKA: 52.21 )
Ranked among companies with meaningful P/E(ttm) only.
HSKA' s P/E(ttm) Range Over the Past 10 Years
Min: 0.49  Med: 34.1 Max: 604
Current: 52.21
0.49
604
Forward P/E 41.15
HSKA's Forward P/E is ranked lower than
83% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.70 vs. HSKA: 41.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 52.21
HSKA's PE(NRI) is ranked lower than
79% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.55 vs. HSKA: 52.21 )
Ranked among companies with meaningful PE(NRI) only.
HSKA' s PE(NRI) Range Over the Past 10 Years
Min: 0.49  Med: 34.17 Max: 604
Current: 52.21
0.49
604
P/B 5.42
HSKA's P/B is ranked lower than
70% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.35 vs. HSKA: 5.42 )
Ranked among companies with meaningful P/B only.
HSKA' s P/B Range Over the Past 10 Years
Min: 0.22  Med: 1.27 Max: 25.79
Current: 5.42
0.22
25.79
P/S 3.93
HSKA's P/S is ranked lower than
59% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. HSKA: 3.93 )
Ranked among companies with meaningful P/S only.
HSKA' s P/S Range Over the Past 10 Years
Min: 0.12  Med: 0.78 Max: 4.11
Current: 3.93
0.12
4.11
PFCF 472.90
HSKA's PFCF is ranked lower than
99% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.43 vs. HSKA: 472.90 )
Ranked among companies with meaningful PFCF only.
HSKA' s PFCF Range Over the Past 10 Years
Min: 2.43  Med: 17.87 Max: 511.04
Current: 472.9
2.43
511.04
POCF 95.41
HSKA's POCF is ranked lower than
96% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.33 vs. HSKA: 95.41 )
Ranked among companies with meaningful POCF only.
HSKA' s POCF Range Over the Past 10 Years
Min: 2.36  Med: 25.24 Max: 451.21
Current: 95.41
2.36
451.21
EV-to-EBIT 33.19
HSKA's EV-to-EBIT is ranked lower than
77% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.82 vs. HSKA: 33.19 )
Ranked among companies with meaningful EV-to-EBIT only.
HSKA' s EV-to-EBIT Range Over the Past 10 Years
Min: -111.6  Med: 22.25 Max: 172
Current: 33.19
-111.6
172
EV-to-EBITDA 25.22
HSKA's EV-to-EBITDA is ranked lower than
73% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.42 vs. HSKA: 25.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSKA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43  Med: 12.65 Max: 58.4
Current: 25.22
-43
58.4
PEG 3.11
HSKA's PEG is ranked lower than
53% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. HSKA: 3.11 )
Ranked among companies with meaningful PEG only.
HSKA' s PEG Range Over the Past 10 Years
Min: 41.36  Med: 51.7 Max: 65.79
Current: 3.11
41.36
65.79
Shiller P/E 62.07
HSKA's Shiller P/E is ranked lower than
76% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.55 vs. HSKA: 62.07 )
Ranked among companies with meaningful Shiller P/E only.
HSKA' s Shiller P/E Range Over the Past 10 Years
Min: 7.39  Med: 20.13 Max: 254.5
Current: 62.07
7.39
254.5
Current Ratio 2.76
HSKA's Current Ratio is ranked higher than
56% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. HSKA: 2.76 )
Ranked among companies with meaningful Current Ratio only.
HSKA' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.95 Max: 5.19
Current: 2.76
1.03
5.19
Quick Ratio 1.62
HSKA's Quick Ratio is ranked lower than
64% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. HSKA: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
HSKA' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 1.1 Max: 4.4
Current: 1.62
0.56
4.4
Days Inventory 93.84
HSKA's Days Inventory is ranked lower than
52% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 85.13 vs. HSKA: 93.84 )
Ranked among companies with meaningful Days Inventory only.
HSKA' s Days Inventory Range Over the Past 10 Years
Min: 82.09  Med: 106.38 Max: 109.49
Current: 93.84
82.09
109.49
Days Sales Outstanding 48.49
HSKA's Days Sales Outstanding is ranked higher than
71% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.09 vs. HSKA: 48.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSKA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.35  Med: 49.25 Max: 56.31
Current: 48.49
41.35
56.31
Days Payable 31.33
HSKA's Days Payable is ranked lower than
75% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.24 vs. HSKA: 31.33 )
Ranked among companies with meaningful Days Payable only.
HSKA' s Days Payable Range Over the Past 10 Years
Min: 26.98  Med: 36.54 Max: 46.37
Current: 31.33
26.98
46.37

Buy Back

vs
industry
vs
history
Dividend Growth (3y) -100.00
HSKA's Dividend Growth (3y) is ranked lower than
94% of the 32 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.30 vs. HSKA: -100.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
HSKA' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: -100
Current: -100
Yield on cost (5-Year) 0.90
HSKA's Yield on cost (5-Year) is ranked lower than
65% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.39 vs. HSKA: 0.90 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
HSKA' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.79  Med: 2.22 Max: 3.73
Current: 0.9
0.79
3.73
3-Year Average Share Buyback Ratio -7.30
HSKA's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. HSKA: -7.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HSKA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -38.6  Med: -1.7 Max: -0.4
Current: -7.3
-38.6
-0.4

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 125.50
HSKA's Price/Net Current Asset Value is ranked lower than
97% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. HSKA: 125.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
HSKA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.37  Med: 3.86 Max: 207.5
Current: 125.5
2.37
207.5
Price/Tangible Book 8.56
HSKA's Price/Tangible Book is ranked lower than
72% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.57 vs. HSKA: 8.56 )
Ranked among companies with meaningful Price/Tangible Book only.
HSKA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.3  Med: 2.24 Max: 261.43
Current: 8.56
0.3
261.43
Price/Projected FCF 7.34
HSKA's Price/Projected FCF is ranked lower than
88% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. HSKA: 7.34 )
Ranked among companies with meaningful Price/Projected FCF only.
HSKA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.04 Max: 20.8
Current: 7.34
0.57
20.8
Price/Median PS Value 5.07
HSKA's Price/Median PS Value is ranked lower than
99% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. HSKA: 5.07 )
Ranked among companies with meaningful Price/Median PS Value only.
HSKA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.1 Max: 10.05
Current: 5.07
0.21
10.05
Price/Graham Number 4.46
HSKA's Price/Graham Number is ranked lower than
73% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. HSKA: 4.46 )
Ranked among companies with meaningful Price/Graham Number only.
HSKA' s Price/Graham Number Range Over the Past 10 Years
Min: 0.2  Med: 2.2 Max: 18.59
Current: 4.46
0.2
18.59
Earnings Yield (Greenblatt) (%) 3.00
HSKA's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.94 vs. HSKA: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HSKA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 4 Max: 21.2
Current: 3
0.6
21.2
Forward Rate of Return (Yacktman) (%) -2.66
HSKA's Forward Rate of Return (Yacktman) (%) is ranked lower than
77% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.70 vs. HSKA: -2.66 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HSKA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.3  Med: -2.2 Max: 7.5
Current: -2.66
-15.3
7.5

More Statistics

Revenue (TTM) (Mil) $120.3
EPS (TTM) $ 1.25
Beta0.43
Short Percentage of Float2.86%
52-Week Range $26.26 - 69.80
Shares Outstanding (Mil)6.90

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 126 144 162 177
EPS ($) 1.39 1.59 1.97 2.40
EPS w/o NRI ($) 1.39 1.59 1.97 2.40
EPS Growth Rate
(3Y to 5Y Estimate)
30.70%
Dividends Per Share ($)
» More Articles for HSKA

Headlines

Articles On GuruFocus.com
'Kittens Equal Happiness': GAMCO Analyst on Zoetis, Heska, Smuckers Oct 07 2016 
Heska's Still has Room to Run Aug 19 2016 
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 5,000 Shares Jun 01 2010 
Heska Corp. (HSKA) CEO Robert B Grieve buys 6,500 Shares May 21 2010 
Weekly CFO Buys Highlight: ZixIt, Global Defense Technology and Systems, FelCor Lodging Trust, Heska Mar 07 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 1,000 Shares Mar 01 2010 

More From Other Websites
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S. Dec 01 2016
Time to Focus on Heska (HSKA) for Strong Earnings Growth Potential Nov 30 2016
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor Nov 30 2016
Coverage initiated on Heska Corp by The Benchmark Company Nov 29 2016
Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial Nov 29 2016
Glaxo (GSK) Files Regulatory Application for Shingrix in EU Nov 28 2016
OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S. Nov 25 2016
Juno's ROCKET Study on Clinical Hold Again, Shares Down Nov 24 2016
Is Heska (HSKA) Stock a Solid Choice Right Now? Nov 23 2016
Allergan's Fibristal Approved in Canada for Label Expansion Nov 22 2016
Agios Presents Data from Dose Expansion Study of AG-120 Nov 21 2016
Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017 Nov 21 2016
Earnings Estimates Moving Higher for Heska (HSKA); Time to Buy? Nov 17 2016
ACADIA Starts Phase II Schizophrenia Study on Pimavanserin Nov 16 2016
Lily's Jardiance Effective in Lowering Cardiovascular Death Nov 14 2016
HESKA CORP Financials Nov 11 2016
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte Nov 11 2016
Sucampo (SCMP) Beats Q3 Earnings & Revenues, Guides Up Nov 10 2016
Zacks.com featured highlights: Heska, Teradyne, Nxstage Medical, Unifi and Rollins Nov 09 2016
Heska (HSKA) Shares March Higher, Can It Continue? Nov 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)